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BC: breast cancer  
DNA: Deoxyribonucleic acid 
HR: Hazard Ratios 
HRR :  Hazard Ratios for retrospective cohort 
HRP :  Hazard Ratios for prospective cohort 
CI: confidence interval 
FFTP: first full-term pregnancy 
RRM: risk-reducing mastectomy 
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Background: Tobacco smoking and alcohol consumption have been intensively studied in 
the general population to assess their effects on the risk of breast cancer (BC), but very few 
studies have examined these effects in BRCA1 and BRCA2 mutation carriers. Given the high 
BC risk for mutation carriers and the importance of BRCA1 and BRCA2 in DNA repair, better 
evidence on the associations of these lifestyle factors with BC risk is essential. 
Methods: Using a large international pooled cohort of BRCA1 and BRCA2 mutation carriers, 
we conducted retrospective (5,707 BRCA1 mutation carriers; 3,525 BRCA2 mutation carriers) 
and prospective (2,276 BRCA1 mutation carriers; 1,610 BRCA2 mutation carriers) analyses of 
alcohol and tobacco consumption using Cox proportional hazards models.  
Results: For both BRCA1 and BRCA2 mutation carriers, none of the smoking-related 
variables was associated with BC risk, except smoking for more than five years before a first 
full-term pregnancy (FFTP) when compared to parous women who never smoked. For 
BRCA1 mutation carriers, the HR from retrospective analysis (HRR) was 1.19 
(95%CI:1.02,1.39) and the HR from prospective analysis (HRP) was 1.36 (95%CI:0.99,1.87). 
For BRCA2 mutation carriers, smoking for more than five years before a FFTP showed an 
association of a similar magnitude, but the confidence limits were wider 
(HRR=1.25,95%CI:1.01,1.55 and HRP=1.30,95%CI:0.83,2.01). For both carrier groups, 
alcohol consumption was not associated with BC risk.  
Conclusions: The finding that smoking during the pre-reproductive years increases BC risk 
for mutation carriers warrants further investigation. 
Impact: This is the largest prospective study of BRCA mutation carriers to assess these 
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Carriers of pathogenic variants (mutations) in the BRCA1 and BRCA2 genes are at 
very high risk of developing breast cancer (BC) and ovarian cancer.  We recently reported 
cumulative risks of BC to 80 years of 72% (95% CI, 65%-79%) for BRCA1 mutation carriers 
and 69% (95% CI, 61%-77%) for BRCA2 mutation carriers based on prospective follow-up 
of unaffected female mutation carriers (1).  However, the associations of lifestyle risk factors 
on BC risk for BRCA1 and BRCA2 (BRCA1/2) mutation carriers remain uncertain. The 
Oxford collaborative reanalysis of 53 epidemiological studies concluded that for women 
unselected for family history, alcohol consumption was associated with increased BC risk 
while there was no association between smoking and BC risk (2). However, some recent 
studies have found that BC risk may be increased if smoking starts early in life, i.e., before 
menarche or a first full-term pregnancy (FFTP) (3 - 5) . Of the studies that have attempted to 
identify lifestyle factors that modify BC risk for BRCA mutation carriers, few have examined 
associations with smoking or alcohol consumption and the results are inconsistent (6-15), 
possibly due to methodological limitations and small sample sizes. In view of the very high 
BC risk for BRCA1/2 mutation carriers, together with the well-known carcinogenic and 
mutagenic activity of alcohol metabolites (16) and tobacco components (17) and the 
widespread consumption of alcohol and tobacco, it is important to derive reliable estimates of 
the associations of alcohol and tobacco consumption with BC risk for BRCA1 and BRCA2 
mutation carriers. Moreover, given the role of BRCA1 and BRCA2 in DNA repair, it is 
plausible that smoking and alcohol consumption could have a disproportionate effect for 
mutation carriers at least in terms of absolute risk. Further, recent experimental data have 
shown a haplo-insufficiency for BRCA2 and a replication fork instability in BRCA2 
heterozygous cells induced by acetaldehyde, an endogenous product of alcohol catabolism 
(18). 
 
To provide more reliable estimates of the associations of these lifestyle factors with 
BC risk for mutation carriers, we analyzed data from the largest available cohort of nearly 
10,000 BRCA1 and BRCA2 mutation carriers (1) and compared the results from this 
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Materials and Methods 
Study design 
We harmonized risk factor and follow-up data from three prospective cohorts: The 
International BRCA1/2 Carrier Cohort Study (IBCCS) (19), the Kathleen Cuningham 
Foundation Consortium for Research Into Familial Breast Cancer (kConFab) Follow-Up 
Study (20,21), and the Breast Cancer Family Registry (BCFR) (22). The combined cohort 
(“The BRCA1 and BRCA2 Cohort Consortium”) included data from 21 centres in Western 
countries (supplemental Table 1S). The total cohort enrolled 9,845 BRCA1 and BRCA2 
mutation carriers aged 18-80 years (after excluding 14 carriers of a mutation in both genes) 
(19, 23). Sixty-six percent of the study participants were enrolled in one of the five ongoing 
nationwide studies in the United Kingdom and Ireland (Epidemiological Study of Familial 
Breast Cancer [EMBRACE]), France (Gene Etude Prospective Sein Ovaire [GENEPSO]), the 
Netherlands (Hereditary Breast and Ovarian cancer study Netherlands [HEBON]), Australia 
and New Zealand (kConFab) or Austria (Medical University of Vienna [MUV]). The other 
studies were based on regional clinical genetic centers or were population-based (3 centers of 
the BCFR).  
 
Study participants and Data Collection 
Women were eligible for this analysis if they were 18-80 years of age and had tested 
positive for a pathogenic BRCA1 or BRCA2 mutation. The total group with follow-up for a 
first BC and eligible for retrospective or prospective analyses consisted of 9,845 women 
(9,232 for retrospective and 3,886 for prospective analysis), including 6,032 BRCA1 and 
3,813 BRCA2 mutation carriers (Figure 1). Women who were unaffected with breast cancer 
at baseline were excluded from prospective analyses if either: they had ovarian cancer (415 
BRCA1 carriers, 142 BRCA2); other cancer (146 BRCA1, 141 BRCA2; Risk-reducing 
mastectomy (RRM) (298 BRCA1; 139 BRCA2); or did not have follow-up data (360 BRCA1; 
226 BRCA2). Participants provided written informed consent and each study was approved 
by the relevant ethical committee. Study participants were invited to complete a baseline 
questionnaire at enrolment and regular follow-up questionnaires. The questionnaires 
requested detailed information on known or suspected risk factors for breast and ovarian 
cancer. The primary sources of information on cancer occurrence were: self-report via 
questionnaire only (6 studies, 8% of the study group), self-report with medical record 
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validation (2 studies, 37%), medical records (4 studies, 18%), and linkage to cancer registries 
(4 studies, 37%), although some studies had a mix of these diagnostic sources. Information 
on vital status was obtained from municipal or death registries or from contact with family 
members.  
 
Assessment of alcohol consumption and cigarette smoking  
We collected information on ever smoking (defined as at least one pack of cigarettes 
per month for one year), current smoking intensity (average number of cigarettes per day), 
age started smoking, age stopped smoking, and total duration of smoking (in years) and 
average number of cigarettes per day during this period. Questionnaires also asked about ever 
alcohol use (at least one glass per month for one year), alcohol use in the last year (i.e., 
current use), and total years of consumption. In most studies separate questions were asked 
about types of alcohol and for each type the amount consumed per week. Some studies asked 
about alcohol use at age 20 years; women in studies without this information (e.g. BCFR) 
were treated as missing for variables related to alcohol consumption at age 20 years.  
After data harmonization across studies, smoking variables were converted to 
ever/never smoking, number of cigarettes per day (current or past for ex-smokers) in five 
categories (0; 1-5, 6-10, 11-20, >20), years of smoking and estimated number of pack-years 
in 3 categories (<1, 1-20, >20), age started in 3 categories (<= 15 years, 16-19, >= 20 years) 
and timing relative to their FFTP. Alcohol variables were converted to ever/never, and total 
average number of standard drinks per day at age 20 years and in the year prior to completing 
the questionnaire.  
 
Statistical analysis 
To assess the association between alcohol and tobacco consumption and the risk of BC, we 
used Cox proportional hazards regression models. Women were eligible for prospective 
analyses if they were free of cancer and had no history of risk-reducing mastectomy (RRM) 
at the start of follow-up (enrolment/baseline questionnaire or mutation test, whichever came 
last); for participants recruited in a research setting, follow-up was considered to begin at 
enrolment. The primary endpoint was BC (invasive (n=393) or in situ (n=33) for the 
prospective analyses) diagnosed more than one month after enrolment. The censoring event 
was the first of diagnosis of primary BC (invasive or in situ), diagnosis of another cancer, 
Research. 
on January 29, 2020. © 2019 American Association for Cancercebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 2, 2019; DOI: 10.1158/1055-9965.EPI-19-0546 
11 
 
RRM, last questionnaire, last information from external source (e.g., linkage), loss to follow-
up, age 80 years, or death.  Alcohol and tobacco variables were analyzed as fixed in the 
models because timing of changes in consumption was too uncertain to generate time-
dependent variables.  Analyses were adjusted for alcohol consumption (ever vs. never) when 
tobacco consumption was analyzed and for smoking (ever vs. never) when alcohol 
consumption was analyzed. Because the consumption of alcoholic beverages and tobacco 
consumption might interact with other BC risk factors (24, 25), we also performed analyses 
adjusted on additional potential confounders like age at menarche (<12, ≥12 - <13, ≥13 - <14, 
≥14 - <15, >=15, age missing or never had menstrual period), age at 1st full-term pregnancy 
(<30, ≥30+nulliparous), number of full-term pregnancies (0, 1, ≥2), body mass index (<18.5, 
18.5–24.9, 25–29.9,30 or greater, missing), oral contraceptive use (ever, never, missing), 
bilateral oophorectomy (yes, no), and number of affected relatives with breast cancer (0, 1, 
≥2, Unknown). We conducted separate analyses for BRCA1 and BRCA2 mutation carriers. 
We stratified for birth cohort and study and used robust variance estimation to account for 
familial clustering.  
 
In addition to the prospective analysis, we conducted full-cohort retrospective 
analyses, in which follow-up was assumed to start at birth and women were followed until the 
first of diagnosis of primary BC (invasive or in situ), diagnosis of another cancer, RRM, start 
of prospective follow-up (baseline questionnaire or mutation test, whichever came last) or 
age 80 years. Thus, there was no overlap in follow-up period for individual women included 
in the retrospective and prospective analyses. Due to non-random sampling of prevalent cases 
of BC, all analyses of retrospective data were performed using the weighted regression 
approach described by Antoniou et al (26). Since changes in habits might occur after a BC 
diagnosis, the number of glasses per day consumed during the last year and the number of pack 
years at the date of baseline questionnaire were not included in the retrospective analyses.   
 
To minimize potential survival bias, we also conducted an additional retrospective 
analysis of a pseudo-incident cohort, which was defined as follow-up starting five years 
before enrolment/baseline questionnaire, and thus only included cases diagnosed within the 5 
years prior to enrolment.  
 
Analyses were stratified by birth cohort into four groups (<=1950, 1951-1959, 1960-
1968, >=1969 for retrospective analyses and <=1957, 1958-1966, 1967-1974, >=1975 for 
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prospective analyses). We also assessed associations by birth cohort and study. All statistical 




Tables 1 and 2 summarize the descriptive statistics of the two cohorts of BRCA1 and 
BRCA2 mutation carriers, respectively. Comparison of the retrospective and prospective 
analysis identified differences in distributions of cigarette consumption: we observed more 
ex-smokers and never smokers (i.e., non-current smokers) in the retrospective analysis than 
in the prospective analysis for both BRCA1 (84.9% vs. 75.5% for cases, 81.1% vs. 79.0% for 
unaffected women) and BRCA2 (85.0% vs. 84.1% for cases, 82.4 % vs. 81.3% for unaffected 
women) mutation carriers.  
 
BRCA1 mutation carriers: 
 
For BRCA1 mutation carriers, there were no associations between BC risk and the alcohol  
measures examined, except for reduced risk associated with higher alcohol consumption in 
the retrospective analysis, with an HRR of 0.59 (95%CI:0.43,0.81; p=0.001) for more than 
two glasses of alcohol consumed at age 20 years when compared to 0 glasses of alcohol 
(Table 3). However, no associations were observed with alcohol consumption at age 20 years 
or at baseline in the prospective analyses.  
 
There were no associations with ever smoking, number of cigarettes smoked, pack-
years, or age at start smoking, in either the prospective or retrospective analysis. However, 
among parous women, increased BC risk was associated with more than 5 years of smoking 
before their FFTP in both prospective and retrospective analyses when compared to parous 
women who never smoked (HRR=1.19, 95%CI 1.02,1.39; and HRP=1.36, 95%CI:0.99,1.87, 
respectively). Among nulliparous women, there was no evidence of an association with ever 
smoking when compared to never smoking (HRR=0.97, 95%CI: 0.74,1.27); and HRP=1.20, 
95%CI: 0.68,2.12). Figure 2 displays the cumulative risks of BC for women who smoked for 
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BRCA2 mutation carriers: 
 
Both ever use of smoking and alcohol drinking were associated with increased BC 
risk when compared to women who neither smoked nor drank alcohol for BRCA2 mutation 
carriers, but only in the retrospective analysis (ever alcohol consumption in non-smokers 
HRR=1.32, 95%CI: 1.03,1.70; p=0.03; ever smoking in non-drinkers HRR=1.37, 
95%CI:1.00,1.89; p=0.05, ever alcohol and ever smoking (i.e., at least one glass per month 
for one year plus at least one pack of cigarettes per month for one year); HRR=1.43, 
95%CI:1.13,1.81; p=0.003) (Table 4). Similar to the findings for BRCA1 mutation carriers, in 
both prospective and retrospective analyses we observed an increased BC risk associated with 
having smoked more than 5 years before a FFTP (HRR=1.25, 95%CI:1.01,1.55; and 
HRP=1.30, 95%CI:0.83,2.02, respectively), but the estimates were statistically significant 




Results from retrospective analyses that used the pseudo-incident cohort were 
consistent with those from the full-cohort retrospective analyses except for BRCA1 mutation 
carriers where smoking more than 5 years before a FFTP point estimate slightly lowered and 
significance disappeared (Supplementary Data, Table 2S).  We observed no significant 
heterogeneity in the HRs for smoking more than 5 years before a FFTP (Supplemental 
Figures 1 and 2), with the exception of heterogeneity by birth cohort for the prospective 
analysis for BRCA1 mutation carriers which is due to the most recent birth cohort where the 
HRp was high, though bounded by a large confidence interval (see Supplemental Figure 2a). 
There was no significant heterogeneity by study group with regard to the association we 
observed for high alcohol consumption in the retrospective analysis for BRCA1 or BRCA2 
mutation carriers (p=0.19 and 0.14, respectively) (data not shown).  
 
In our primary analyses we did not adjust the analyses for other possible confounders 
since most of the other risk factors for BC are unlikely to be correlated with the primary 
alcohol and smoking exposures of interest. The multivariable-adjusted results are presented in 
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Supplementary Tables 3S and 4S. As expected, multivariable adjustment did not materially 
change the HR estimates and more importantly, the overall conclusions of the study.  
 
We performed separate analyses for BRCA1 and BRCA2 cohorts based on the 
hypothesis that the role of the two genes may be different in response to carcinogens from 
alcohol and tobacco. However, we also performed a pooled analysis which, again, did not 
change drastically our initial findings nor our conclusions (Table 5S). 
 
Discussion 
Using data from the largest international cohort of BRCA1 and BRCA2 mutation 
carriers, we examined associations with alcohol consumption and smoking separately using 
both independent retrospective and prospective data. We found no evidence of an overall 
association between cigarette consumption with BC risk, except for the BRCA2 mutation 
carriers in the retrospective analysis. However, among parous women, we observed that 
mutation carriers who smoked more than five years before their FFTP had a significantly 
increased risk of BC. This association was seen in both prospective and retrospective 
analyses, and was seen for both BRCA1 and BRCA2 mutation carriers, though the confidence 
limits for BRCA2 mutation carriers were wider.  The consistency of these findings for 
mutations carriers of either gene as well as similar point estimates between prospective and 
retrospective analyses support the overall conclusion that this time window prior to breast 
tissue differentiation from pregnancies may be a particularly sensitive window for 
environmental carcinogenesis.   
 
Unlike in the general population (2, 27) and in accordance with other studies on 
BRCA1 and BRCA2 mutation carriers (6, 28), our findings do not support a positive 
association between alcohol intake and BC risk, although power was somewhat limited to 
detect the relatively modest association observed in prior studies (3, 27). 
 
Findings from studies that have examined associations between smoking and BC risk 
for BRCA1 and BRCA2 mutation carriers have been inconsistent. Some reported a null 
association (12-15), two reported a negative association (9, 10), and two reported a positive 
association (8, 13), although the latter study showed this association only for BRCA1 
mutation carriers with a past history of smoking (13). While retrospective studies have the 
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advantage of larger size and full life history of smoking, prospective studies have the 
advantage that reporting of behaviors is not influenced by disease.   
 
In our study, women with BRCA1 mutations who drank more than two glasses of 
alcohol per day were at decreased BC risk, but only in the retrospective analyses. This 
discrepancy in results between the two designs for heavier consumers might be explained by 
survival bias. While tobacco consumption has been suggested as a poor prognostic factor, 
particularly for women with a diagnosis of triple negative and luminal A-like breast tumours 
(29), the  association of alcohol with prognosis is less clear. Regular drinking of 0.5 standard 
drinks or more per day has been shown to be associated with higher risk of BC recurrence, 
particularly among postmenopausal women (30). Therefore, if women who are heavy 
consumers are more likely to die after a diagnosis of BC than non-drinking women with BC, 
the inclusion of prevalent cases in a retrospective analysis may bias results toward unity or 
even lead to an artifactual negative association (8).  
 
Major strengths of our study include the large sample size for both retrospective and 
prospective cohorts with very good follow-up and the largest number of BRCA1 and BRCA2 
prospective mutation carrier BC cases studied to date. Potential weaknesses include the fact 
that information on alcohol intake and tobacco consumption was self-reported with 
accompanying potential exposure misclassification and the potential for the retrospective 
analyses to be affected by survival bias due to the inclusion of prevalent cases. However, the 
prospective part of our study minimized recall and survival biases.   
As in the general population (5), we found a consistent association of increased BC risk with 
cigarette smoking for mutation carriers who smoked for more than 5 years before their FFTP. 
The period preceding a FFTP has been shown to be a critical period for breast carcinogenesis 
(31, 32), particularly for women with a mutation in BRCA1 or BRCA2 (33), and potentially 
even more so for women who accumulated DNA defects during the years before a FFTP 
because of smoking (Figure 2).  
 
With the exception of the association with smoking for more than five years before a FFTP, 
no associations were found for most smoking-related variables for either BRCA1 or BRCA2 
mutation carriers. Similarly, no association with alcohol consumption was found in the 
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prospective analysis. However, associations with these two lifestyle factors might be complex 
and need more detailed information on consumption (e.g., quantities and calendar years of 
starting and stopping) and timing to be able to prospectively investigate them as time-
dependent exposures and extended follow-up might shed further light upon associations of 
smoking and alcohol with BC risk for BRCA1 and BRCA2 mutation carriers. 
 
In summary, we found no substantial association of BC risk with alcohol consumption or 
smoking except for women who smoked for more than five years before their FFTP. These 
findings suggest that smoking during the pre-reproductive years may increase BC risk for 
mutation carriers, warranting further investigation.  
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Table 1. Characteristics of the BRCA1 mutation carriers 
  
Women with Breast Cancer Unaffected Women 
retrospective prospective retrospective prospective 









Age at Entry   
 
40.7 ± 10.3 
 
37.5 ± 11.8 
Age at Censure 40.1 ± 8.8 44.9 ± 10.3 39.3 ± 11.6 43.1 ± 12.3 
Year of Birth 
    
<1950 804 (31.7) 35 (13.0) 527 (16.6) 205 (10.2) 
1950 - 1959 842 (33.2) 76 (28.3) 647 (20.4) 347 (17.3) 
1960 - 1969 662 (26.1) 104 (38.7) 946 (29.8) 586 (29.2) 
≥1970 229 (9.0) 54 (20.1) 1050 (33.1) 869 (43.3) 
Study Group 
    
EMBRACE 743 (29.3) 41 (15.2) 817 (25.8) 432 (21.5) 
GENEPSO 324 (12.8) 46 (17.1) 692 (21.8) 442 (22.0) 






BCFR 456 (18.0) 50 (18.6) 433 (13.7) 277 (13.8) 
Others§ 677 (26.7) 37 (13.8) 763 (24.1) 384 (19.1) 
Smoking/alcohol status     
Never 567 (22.3) 64 (23.8) 698 (22.0) 457 (22.8) 
Ever, alcohol only 773 (30.5) 65 (24.2) 976 (30.8) 618 (30.8) 
Ever, smoking only 281 (11.1) 29 (10.8) 306 (9.7) 193 (9.6) 
Ever, smoking and  
alcohol 
891 (35.1) 104 (38.7) 1146 (36.2) 713 (35.5) 
missing 25 (1.0) 7 (2.6) 44 (1.4) 26 (1.3) 
Smoking status     
Never 1344 (53.0) 132 (49.1) 1688 (53.2) 1081 (53.9) 
Past smoker 809 (31.9) 71 (26.4) 883 (27.9) 504 (25.1) 
Current smoker 364 (14.3) 63 (23.4) 565 (17.8) 398 (19.8) 
missing 20 (0.8) 3 (1.1) 34 (1.1) 24 (1.2) 
Cigarettes per day (current or past)    
0 1344 (53.0) 132 (49.1) 1688 (53.2) 1081 (53.9) 
< 5 266 (10.5) 32 (11.9) 366 (11.5) 237 (11.8) 
6-10 311 (12.3) 34 (12.6) 414 (13.1) 259 (12.9) 
11-20 417 (16.4) 49 (18.2) 482 (15.2) 294 (14.6) 
> 20 86   (3.4) 14   (5.2) 80  (2.5) 58 (2.9) 
missing 113 (4.5) 8 (3.0) 140 (4.4) 78 (3.9) 
Number of pack-years     
<1 1387 (54.7) 138 (51.3) 1774 (56.0) 1147 (57.1) 
1-20 722 (28.5) 96 (35.7) 976 (30.8) 628 (31.3) 
>20 281 (11.1) 26 (9.7) 238 (7.5) 132 (6.6) 
missing 147 (5.8) 9 (3.3) 182 (5.7) 100 (5.0) 
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Women with Breast Cancer Unaffected Women 
retrospective prospective retrospective prospective 









Age started smoking (years) 
Never  1344 (53.0) 132 (49.1) 1688 (53.2) 1081 (53.9) 
< 15 233 (9.2) 33 (12.3) 364 (11.5) 240 (12.0) 
16-19 487 (19.2) 69 (25.7) 576 (18.2) 385 (19.2) 
    >20 190 (7.5) 15 (5.6) 194 (6.1) 106 (5.3) 
missing 283 (11.2) 20 (7.4) 348 (11.0) 195 (9.7) 
Glasses of alcohol per day in 
past year  £  
    
0 1017 (40.1) 108 (40.1) 1222 (38.5) 772 (38.5) 
<1 830 (32.7) 72 (26.8) 955 (30.1) 560 (27.9) 
1-2 430 (16.9) 48 (17.8) 588 (18.5) 391 (19.5) 
>2 93 (3.7) 12 (4.5) 217 (6.8) 143 (7.1) 
missing 167 (6.6) 29 (10.8) 188 (5.9) 141 (7.0) 
Glasses of alcohol per day at 
age 20 years 
    
0 804 (31.6) 65 (24.2) 992 (31.3) 520 (25.9) 
<1 670 (26.4) 41 (15.2) 785 (24.8) 421 (21.0) 
1-2 292 (11.5) 22 (8.2) 470 (14.8) 269 (13.4) 
>2 64 (2.5) 9 (3.4) 183 (5.8) 111 (5.5) 
missing 707 (27.9) 132 (49.1) 740 (23.3) 686 (34.2) 
§ Others included the following studies (total number):  MUV-Austria (261), MODSQUAD (228), GC-HBOC (178), Lund-BRCA 
(160), OUH (105), HCSC (84), INHERIT (66), NIO-Hungry (98), IHCC (97), Stockholm-BRCA (71), CNIO (40), Milan Italy (33), 
HSP (9), DKFZ (4), Belgium (3), Dusseldorf Germany (3).  
£ Year preceding completion of last questionnaire 
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Table 2. Characteristics of the BRCA2 mutation carriers 
                        
Women with Breast Cancer Unaffected Women 
retrospective Prospective retrospective prospective 
(N=1555) (N=157) (N=1970) (N=1453) 







Age at Start 
 
45.1 ± 10.1 
 
40.0 ± 12.6 
Age at Censure 43.4 ± 9.1 49.0 ± 10.3 41.4 ± 12.4 45.0 ± 13.0 
Year of Birth 
    
<1950 563 (36.2) 42 (26.8) 386 (19.6) 200 (13.8) 
1950 - 1959 510 (32.8) 44 (28.0) 388 (19.7) 259 (17.8) 
1960 - 1969 385 (24.8) 55 (35.0) 572 (29.0) 433 (29.8) 
≥1970 97 (6.2) 16 (10.2) 624 (31.7) 561 (38.6) 
Study Group 
    
EMBRACE 611 (39.3) 42 (26.8) 744 (37.8) 441 (30.4) 
GENEPSO 161 (10.4) 18 (11.5) 437 (22.2) 307 (21.1) 






BCFR 359 (23.1) 33 (21.0) 322 (16.3) 222 (15.3) 
Others§ 334 (21.5) 22 (14.0) 320 (16.2) 162 (11.1) 
Smoking/alcohol status     
Never 321 (20.6) 44 (28.0) 440 (22.3) 361 (24.8) 
Ever, alcohol only 486 (31.3) 41 (26.1) 632 (32.1) 459 (31.6) 
Ever, smoking only 134 (8.6) 13 (8.3) 154 (7.8) 110 (7.6) 
Ever, smoking and  
alcohol 
597 (38.4) 56 (35.7) 722 (36.6) 512 (35.2) 
missing 17 (1.1) 3 (1.9) 22 (1.1) 11 (0.8) 
Smoking status     
Never 808 (52.0) 85 (54.1) 1079 (54.8) 824 (56.7) 
Past smoker 514 (33.1) 47 (29.9) 544 (27.6) 357 (24.6) 
Current smoker 218 (14.0) 21 (13.4) 334 (17.0) 264 (18.2) 
missing 15 (1.0) 4 (2.5) 13 (0.7) 8 (0.6) 
Cigarettes per day (current or past)    
0 808 (52.0) 85 (54.1) 1079 (54.8) 824 (56.7) 
< 5 158 (10.2) 15 (9.6) 212 (10.8) 154 (10.6) 
6-10 202 (13.0) 24 (15.3) 232 (11.8) 173 (11.9) 
11-20 262 (16.8) 19 (12.1) 316 (16.0) 214 (14.7) 
> 20 55 (3.5) 7 (4.5) 59 (3.0) 49 (3.4) 
missing 70 (4.5) 7 (4.5) 72 (3.7) 39 (2.7) 
Number of Pack-years     
<1 846 (54.4) 90 (57.3) 1126 (57.2) 862 (59.3) 
1-20 430 (27.7) 44 (28.0) 578 (29.3) 434 (29.9) 
>20 197 (12.7) 16 (10.2) 179 (9.1) 111 (7.6) 
missing 82 (5.3) 7 (4.5) 87 (4.4) 46 (3.2) 
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Women with Breast Cancer Unaffected Women 
retrospective Prospective retrospective prospective 
(N=1555) (N=157) (N=1970) (N=1453) 







Age at start smoking (years) 
Never  808 (52.0) 85 (54.1) 1079 (54.8) 824 (56.7) 
< 15 136 (8.7) 19 (12.1) 228 (11.6) 148 (10.2) 
16-19 302 (19.4) 23 (14.6) 358 (18.2) 290 (20.0) 
    >20 153 (9.8) 20 (12.7) 154 (7.8) 102 (7.0) 
missing 156 (10.0) 10 (6.4) 151 (7.7) 89 (6.1) 
Glasses of alcohol per day 
past year£  
    
0 596 (38.3) 68 (43.3) 754 (38.3) 568 (39.1) 
<1 574 (36.9) 41 (26.1) 605 (30.7) 420 (28.9) 
1-2 280 (18.0) 30 (19.1) 375 (19.0) 264 (18.2) 
>2 57 (3.7) 7 (4.5) 166 (8.4) 118 (8.1) 
missing 48 (3.1) 11 (7.0) 70 (3.6) 83 (5.7) 
Glasses of alcohol per day at 
age 20 years  
    
0 424 (27.3) 31 (19.7) 592 (30.1) 345 (23.7) 
<1 439 (28.2) 32 (20.4) 489 (24.8) 283 (19.5) 
1-2 201(12.9) 15 (9.6) 337 (17.1) 219 (15.1) 
>2 56 (3.6) 3 (1.9) 132 (6.7) 89 (6.1) 
missing 435 (28.0) 76 (48.4) 420 (21.3) 517 (35.6) 
 
§ Others included the following studies (total number):  MUV-Austria (100), MODSQUAD (80), GC-HBOC (105), Lund-BRCA 
(58), OUH (62), HCSC (65), INHERIT (74), NIO-Hungry (31), IHCC (0), Stockholm-BRCA (13), CNIO (44), Milan Italy (12), HSP 
(10). 
£ Year preceding completion of last questionnaire 
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Table 3. Association of alcohol and tobacco consumption with breast cancer 
risk for BRCA1 mutation carriers, retrospective (weighted) and prospective 
analyses 
 retrospective P value prospective P value 
 HRa (95% CI)  HRb (95% CI)  
Smoking/alcohol status     
Never 1.00  1.00  
Ever, alcohol only 1.04 (0.89,1.22) 0.63 0.89 (0.61,1.28) 0.52 
Ever, smoke only 1.13 (0.92,1.38) 0.25 0.89 (0.57,1.38) 0.59 
Ever, smoke and  
alcohol 1.04 (0.89,1.22) 0.59 1.16 (0.81,1.65) 0.41 
Cigarettes per day* (current or 
past) 
    
0 1.00  1.00  
< 5 1.01 (0.85,1.21) 0.91 1.25 (0.85,1.85) 0.26 
6-10 1.01 (0.85,1.20) 0.91 1.06 (0.73,1.54) 0.75 
11-20 1.11 (0.95,1.29) 0.20 1.19 (0.86,1.66) 0.30 
> 20 1.16 (0.87,1.55) 0.32 1.26 (0.70,2.27) 0.44 
Continuous (missing excluded)* 1  1.00 (1.00, 1.01)     0.15 11 1.01 (1.00, 1.02) 0.22 
Number of Pack-Years*     
<1  1.00  
1-20 1.21 (0.92,1.58) 0.17 
>20 1.20 (0.78,1.85) 0.40 
Continuous (missing excluded)* 1.01 (1.00, 1.02) 0.12 
Age at start smoking (years)*     
Never 1.00  1.00  
< 15 1.10 (0.90,1.34)          0.34 1.11 (0.75,1.63) 0.60 
    16-19 1.09 (0.94,1.27) 0.25 1.27 (0.93,1.72) 0.13 
>20 1.02 (0.83,1.25) 0.88  1.10 (0.65,1.86) 0.73 
Age at start for parous women 
(years)* 
    
Never 1.00  1.00  
< 15 1.10 (0.89,1.36) 0.37 1.18 (0.79,1.76) 0.42 
16-19 1.12 (0.96,1.32) 0.16 1.24 (0.90,1.73) 0.19 
>20 1.03 (0.83,1.29) 0.77 1.04 (0.57,1.89) 0.90 
Age at start for nulliparous women 
(years)* 
    
Never 1.00  1.00  
< 15 1.28 (0.75,2.19) 0.37 1.22 (0.40,3.68) 0.73 
16-19 0.94 (0.64,1.39) 0.76 1.15 (0.48,2.71) 0.76 
>20 0.86 (0.50,1.49) 0.59 1.80 (0.61,5.31) 0.29 
Smoking and Parity*     
Never smoke & parous 1.00  1.00  
Never smoke & nulliparous 1.31 (1.08,1.60) 0.01 0.70 (0.46,1.07) 0.10 
Ever smoke & nulliparous  1.31 (1.05,1.62) 0.02 0.80 (0.49,1.31) 0.38 
Ever smoke & parous     
5 yrs or less before F FTP 1.01 (0.85,1.20) 0.91 1.11 (0.75,1.66) 0.60 
> 5 yrs before FFTP 1.19 (1.02,1.39) 0.03 1.36 (0.99,1.87) 0.06 
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 retrospective P value prospective P value 
 HRa (95% CI)  HRb (95% CI)  
Glasses of alcohol last year per 
day§ 




<1 0.99 (0.73,1.35) 0.95 
1-2  1.06 (0.76,1.49) 0.74 
>2 0.93 (0.50,1.72) 0.82 
Continuous (per glass)§ 1.02 (0.86,1.21) 0.84 
Glasses of alcohol  per day§ at age 
20  
    
0 1.00  1.00  
<1 1.00 (0.87,1.16) 0.95 0.93 (0.62,1.39) 0.71 
1-2 0.89 (0.74,1.07) 0.21 0.92 (0.57,1.51) 0.75 
>2 0.59 (0.43,0.81) 0.001 1.35 (0.67,2.72) 0.40 
Continuous (per glass)§ 0.88 (0.80,0.96) 0.004 1.04 (0.84,1.28) 0.71 
* Adjusted for alcohol consumption (ever vs. never) 
§ Adjusted for tobacco consumption (ever vs. never).  
a Stratified on birth cohort and 5 study groups for the retrospective analyses 
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Table 4. Association of alcohol and tobacco consumption with BC risk for 






HRa (95% CI) HRb (95% CI) 
Smoking/alcohol status     
Never 1.00  1.00  
Ever, alcohol only 1.32 (1.03,1.70) 0.03 0.77 (0.49,1.20) 0.25 
    Ever, smoking only 1.37 (1.00,1.89) 0.05 0.77 (0.39,1.50) 0.44 
Ever, smoking and  
alcohol 1.43 (1.13,1.81) 0.003 0.98 (0.64,1.52) 0.94 
Cigarettes per day*     
0 1.00  1.00  
< 5 1.08 (0.85,1.37) 0.52 1.06 (0.60,1.85) 0.85 
6-10 1.22 (0.97,1.54) 0.08 1.75 (1.11,2.75) 0.02 
11-20 1.21 (0.98,1.51) 0.08 0.85 (0.51,1.43) 0.55 
> 20 0.97 (0.65,1.43) 0.87 0.74 (0.33,1.69) 0.48 
Number of Pack-Years*     
<1  1.00  
1-20 1.20 (0.82,1.76) 0.34 
>20 0.92 (0.53,1.60) 0.76 
Continuous (missing excluded)* 1.00 (0.98,1.01) 0.75 
Age at start smoking (years)*     
 Never 1.00  1.00  
      < 15 1.15 (0.87,1.50) 0.32 1.23 (0.74,2.06) 0.43 
     16-19 1.29 (1.06,1.58) 0.01 0.79 (0.50,1.26) 0.33 
     >20 0.97 (0.76,1.25) 0.84 1.73 (1.06,2.85) 0.03 
Age at start for parous women 
years)* 
    
Never 1.00    
< 15 1.22 (0.92,1.63) 0.17 1.31 (0.75,2.27) 0.34 
16-19 1.27 (1.02,1.58) 0.03 0.78 (0.48,1.27) 0.32 
>20 0.93 (0.71,1.22) 0.61 1.71 (1.01,2.90) 0.05 
Age at start for nulliparous 
women (years)* 
    
Never 1.00  1.00  
< 15 0.83 (0.26,1.91) 0.66 1.20 (0.28,5.05) 0.81 
16-19 1.67 (1.00,2.77) 0.05 0.88 (0.16,4.90) 0.88 
     >20 1.76 (0.91,3.39) 0.09 1.19 (0.24,5.76) 0.83 
Smoking and Parity*     




Never smoke & nulliparous 1.13 (0.87,1.48) 0.37 0.82 (0.45,1.49) 0.51 
Ever smoke & nulliparous  1.37 (1.02,1.83) 0.04 0.76 (0.35,1.69) 0.51 
Ever smoke & parous 
    
5 yrs or less before FFTP 1.04 (0.84,1.29) 0.72 0.97 (0.59,1.59) 0.89 
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HRa (95% CI) HRb (95% CI) 





<1 0.86 (0.57,1.29) 0.46 
1-2 1.03 (0.66,1.60) 0.91 
>2     0.99 (0.46,2.16) 0.98 
Continuous (per glass)§ 0.93 (0.75,1.17) 0.55 
Glasses of alcohol at age 20 





<1 1.19 (0.98,1.44) 0.08 1.17 (0.70,1.95) 0.55 
1-2 0.97 (0.76,1.23) 0.80 1.09 (0.57,2.08) 0.79 
>2 0.95 (0.65,1.39) 0.79 0.62 (0.18,2.13) 0.45 
Continuous (per glass)§ 1.02 (0.91,1.14) 0.76 0.95 (0.72,1.26) 0.73 
* Adjusted for alcohol consumption (ever vs. never) 
§ Adjusted for tobacco consumption (ever vs. never) 
a Stratified on birth cohort and 5 study groups for the retrospective analyses 
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Figure Legends  
 
Figure 1 : Design of the BRCA1 and BRCA2 cohort consortium. 
Each line represents a sample IBCCS-BCFR-KConFab participant from birth to 
censure: a diagnosis of primary breast cancer (BC); a Risk Reduction Mastectomy 
(RRM); a last FUP questionnaire; and the most recent information from an  external 
source (last linkage). 
B1: BRCA1  B2:  BRCA2 
BC: Breast Cancer 
 
 
Figure 2: Cumulative risk of breast cancer for never smoking parous women and 
those who smoked for more than five years before the first full-term pregnancy 
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